PDS BiotechnologyPDSB
Market Cap: $118M
About: PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Employees: 25
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
224% more call options, than puts
Call options by funds: $827K | Put options by funds: $255K
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
4% more funds holding
Funds holding: 71 [Q1] → 74 (+3) [Q2]
9.79% less ownership
Funds ownership: 24.7% [Q1] → 14.92% (-9.79%) [Q2]
46% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 26
47% less capital invested
Capital invested by funds: $30.4M [Q1] → $16M (-$14.4M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 99 / 262 met price target | 554%upside $21 | Buy Reiterated | 17 Sept 2024 |
Alliance Global Partners | 118%upside $7 | Buy Maintained | 20 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 99 / 262 met price target | 554%upside $21 | Buy Reiterated | 1 Aug 2024 |